行情

SBPH

SBPH

Spring Bk Pharms
NASDAQ

实时行情|Nasdaq Last Sale

1.770
-0.070
-3.80%
盘后: 1.740 -0.03 -1.69% 17:24 01/27 EST
开盘
1.810
昨收
1.840
最高
1.810
最低
1.650
成交量
12.83万
成交额
--
52周最高
11.25
52周最低
1.170
市值
2,916.31万
市盈率(TTM)
-1.3182
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SBPH 新闻

  • 亚太股市全线下跌 航空股受重创
  • 新浪财经.2小时前
  • 特朗普:美国不会为实现与伊朗谈判而解除对伊制裁
  • 新华网.2小时前
  • 日本拟向中国赠送口罩和防护服等援助物资
  • 新浪财经.2小时前
  • Facebook和雷蛇限制员工赴中国旅行
  • 新浪财经.2小时前

更多

所属板块

生物技术和医学研究
-0.88%
制药与医学研究
-0.51%

热门股票

名称
价格
涨跌幅

SBPH 简况

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company's SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).
展开

Webull提供Spring Bank Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。